IvelinRadkov
- AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo (OTCPK:DSKYF) (OTCPK:DSNKY) said that a Phase 3 study of their antibody drug conjugate, or ADC, datopotamab deruxtecan did not show it was able to significantly extend lives versus the chemotherapy drug docetaxel.
- While the study’s results for overall survival favored the drug, also known as Dato-DXd, they did not reach statistical significance, according to a statement.
- The data did show, however, a 2.3 month improvement for Dato-DXd patients with non-squamous non-small cell lung cancer, or NSCLC, with overall survival of 14.6 months, compared with 12.3 months for patients given docetaxel.
- In patients with squamous NSCLC, no overall survival improvement was observed.
- Shares of AstraZeneca closed 3% lower on Monday following the news.
